MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineMTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine, Published online: 05 December 2017; doi:10.1038/tpj.2017.48MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.Pathobiology 2018;85:274 –283
Source: Pathobiology - Category: Pathology Source Type: research
Authors: Zhang Z, Zhao L, Wei X, Guo Q, Zhu X, Wei R, Yin X, Zhang Y, Wang B, Li X Abstract Myeloid disorders, especially myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), cause significant mobility and high mortality worldwide. Despite numerous attempts, the common molecular events underlying the development of MDS and AML remain to be established. In the present study, 18 microarray datasets were selected, and a meta-analysis was conducted to identify shared gene signatures and biological processes between MDS and AML. Using NetworkAnalyst, 191 upregulated and 139 downregulated genes were identifie...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Gao S, Wang H, Jiang H, Fu R, Yu H, Liu C, Tao J, Shao Z Abstract Changes in bone marrow niches can lead to the occurrence of myelodysplastic syndrome (MDS). As an important part of the bone marrow niche, osteoblasts serve a key role in the progression of MDS. The present study investigated the quantity and function of osteoblasts and, through in vitro assays, detected changes in signaling pathways and the association with progression in MDS patients. The ratios of osteoprogenitors (CD34+OCN+) and OCN+CD34-Lin- osteoblasts in MDS patients were significantly less than those of normal controls. The results o...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
European Journal of Haematology,Volume 0, Issue ja, -Not available-.
Source: European Journal of Haematology - Category: Hematology Authors: Source Type: research
American Journal of Hematology,Volume 0, Issue ja, -Not available-.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research
In conclusion, our results suggested that chidamide in combination with decitabine might be an effective therapy for AML. PMID: 30210693 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Conditions:   CD33 Positive;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   CD33 Positive;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Drugs & Pharmacology | Genetics | Myelodysplastic Syndrome